A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
Hanly, John GSu, Li
Urowitz, Murray B
Romero-Diaz, Juanita
Gordon, Caroline
Bae, Sang-Cheol
Bernatsky, Sasha
Clarke, Ann E
Wallace, Daniel J
Merrill, Joan T
Isenberg, David A
Rahman, Anisur
Ginzler, Ellen M
Petri, Michelle
Bruce, Ian N
Dooley, M A
Fortin, Paul
Gladman, Dafna D
Sanchez-Guerrero, Jorge
Steinsson, Kristjan
Ramsey-Goldman, Rosalind
Khamashta, Munther A
Aranow, Cynthia
Alarcón, Graciela S
Fessler, Barri J
Manzi, Susan
Nived, Ola
Sturfelt, Gunnar K
Zoma, Asad A
van Vollenhoven, Ronald F
Ramos-Casals, Manuel
Ruiz-Irastorza, Guillermo
Lim, S Sam
Kalunian, Kenneth C
Inanc, Murat
Kamen, Diane L
Peschken, Christine A
Jacobsen, Soren
Askanase, Anca
Theriault, Chris
Farewell, Vernon
Journal title
Arthritis & rheumatology (Hoboken, N.J.)Publication Volume
68Publication Issue
8Publication Begin page
1932Publication End page
44
Metadata
Show full item recordAbstract
To study bidirectional change and predictors of change in estimated glomerular filtration rate (GFR) and proteinuria in lupus nephritis (LN) using a multistate modeling approach.Patients in the Systemic Lupus International Collaborating Clinics inception cohort were classified annually into estimated GFR state 1 (>60 ml/minute), state 2 (30-60 ml/minute), or state 3 (<30 ml/minute) and estimated proteinuria state 1 (<0.25 gm/day), state 2 (0.25-3.0 gm/day), or state 3 (>3.0 gm/day), or end-stage renal disease (ESRD) or death. Using multistate modeling, relative transition rates between states indicated improvement and deterioration.
Of 1,826 lupus patients, 700 (38.3%) developed LN. During a mean ± SD follow-up of 5.2 ± 3.5 years, the likelihood of improvement in estimated GFR and estimated proteinuria was greater than the likelihood of deterioration. After 5 years, 62% of patients initially in estimated GFR state 3 and 11% of patients initially in estimated proteinuria state 3 transitioned to ESRD. The probability of remaining in the initial states 1, 2, and 3 was 85%, 11%, and 3%, respectively, for estimated GFR and 62%, 29%, and 4%, respectively, for estimated proteinuria. Male sex predicted improvement in estimated GFR states; older age, race/ethnicity, higher estimated proteinuria state, and higher renal biopsy chronicity scores predicted deterioration. For estimated proteinuria, race/ethnicity, earlier calendar years, damage scores without renal variables, and higher renal biopsy chronicity scores predicted deterioration; male sex, presence of lupus anticoagulant, class V nephritis, and mycophenolic acid use predicted less improvement.
In LN, the expected improvement or deterioration in renal outcomes can be estimated by multistate modeling and is preceded by identifiable risk factors. New therapeutic interventions for LN should meet or exceed these expectations.
Citation
Hanly JG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin P, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Alarcón GS, Fessler BJ, Manzi S, Nived O, Sturfelt GK, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Theriault C, Farewell V. A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis Rheumatol. 2016 Aug;68(8):1932-44. doi: 10.1002/art.39674. PMID: 26991067; PMCID: PMC5858760.DOI
10.1002/art.39674ae974a485f413a2113503eed53cd6c53
10.1002/art.39674
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as © 2016, American College of Rheumatology.